|
시장보고서
상품코드
2102163
만성 판상 건선 시장 규모, 점유율, 성장 분석 : 치료법별, 약물 계열별, 투여 경로별, 질환 중증도별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Chronic Plaque Psoriasis Market Size, Share, and Growth Analysis, By Treatment Type, By Drug Class, By Route of Administration, By Disease Severity, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 만성 판상 건선 시장 규모는 2024년에 295억 달러로 평가되었으며, 2025년 315억 1,000만 달러에서 2033년까지 534억 2,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 6.82%로 성장할 것으로 전망됩니다.
세계 만성 판상 건선 시장은 유병률이 높은 이 자가면역 질환의 관리를 목적으로 한 치료법, 진단법 및 환자 지원 서비스의 진화가 특징입니다. 환자의 삶의 질(QOL)에 미치는 큰 영향에 더해, 의료비 증가가 맞물리면서 혁신적인 치료법에 대한 수요가 높아지고 있습니다. 기존에는 외용 코르티코스테로이드가 주류를 이루었으나, 바이오의약품의 등장으로 표적화된 면역 조절이 가능해져 치료 효과가 향상되었습니다. 바이오시밀러의 등장으로, 특히 개발도상국 시장에서 치료 접근성과 합리적인 가격이 개선되고 있습니다. 투자자들은 치료 파이프라인의 진전을 주시하고 있으며, 특히 편의성과 안전성을 높여주는 경구용 저분자 약제가 주목받고 있습니다. 경구용 야누스 키나제 억제제에 따른 복약 순응도 향상은 보험 적용 품목 목록에 영향을 미치며, 전문 의료 분야에서의 도입을 가속화하고 있습니다. 각 제약사는 지속적인 수익 성장과 사업 기반 강화를 도모하기 위해 병용요법 연구 개발에 대한 투자를 확대하고 있습니다.
세계 만성 판상 건선 시장의 성장요인
일반 대중과 의료 종사자들 사이에서 인식이 높아짐에 따라, 만성 판상 건선 환자의 조기 발견과 치료 계획의 적시 시작에 있어 매우 중요한 역할을 하고 있습니다. 이러한 적극적인 접근 방식 덕분에 질환의 진행이 완만해지고 삶의 질이 향상되며, 환자들이 의료 시스템에 적극적으로 참여하게 됩니다. 치료를 원하는 사람들이 늘어남에 따라 효과적인 치료법에 대한 수요는 계속해서 증가하고 있으며, 의료 서비스 제공자들이 다양한 환자의 요구에 부응하는 혁신적인 해결책을 모색함에 따라 시장 확장을 주도하고 있습니다. 또한, 인식 제고 활동을 통해 환자의 복약 순응도가 향상되고, 의사가 첨단 치료법을 처방할 수 있게 됨에 따라 세계 시장의 성장 궤도에 더욱 기여하고 있습니다.
세계 만성 판상 건선 시장의 제약요인
세계 만성 판상 건선 시장은 첨단 치료법에 수반되는 고비용으로 인해 환자, 보험사 및 의료 시스템에 막대한 경제적 부담을 안겨주는 중대한 과제에 직면해 있습니다. 이러한 경제적 부담은 보험 적용 목록에 대한 제한적인 등재나 사전 승인 요건으로 이어지며, 궁극적으로 환자의 접근성을 제한하고 의료 제공자가 고가의 치료법을 처방하는 것을 주저하게 만드는 요인이 됩니다. 그 결과, 혁신적인 치료법의 시장 침투가 둔화되고 있습니다. 또한, 예산 제약으로 인해 제네릭 의약품이나 저비용 대체제의 사용이 우선시되는 경우가 많아, 이로 인해 최첨단 치료법에 대한 수요가 감소하고 제조사의 수익 기회가 제한되고 있습니다. 또한, 비용 대비 효과에 대한 우려로 인해 지불 기관은 리베이트 제공을 요구하는 경향이 있으며, 이는 제품 채택을 저해할 수 있는 추가적인 복잡성을 야기하고 있습니다.
세계 만성 판상 건선 시장 동향
세계 만성 판상 건선 시장은 효과적인 치료를 보다 쉽게 이용할 수 있고 가격도 합리적인 바이오시밀러의 부상으로 인해 큰 변화를 겪고 있습니다. 이러한 바이오시밀러는 기존 생물학적 제제와 동등한 효능을 저렴한 비용으로 제공함으로써 환자 대상 적용 범위를 넓히고, 의료 예산 부담을 경감시키고 있습니다. 지불 기관이 이러한 대체품을 점점 더 지지함에 따라 제약사들은 개발 노력을 강화하고 있으며, 그 결과 시장 경쟁이 격화되고 있습니다. 이러한 경쟁 구도로 인해 오리지널 생물학적 제제 개발 기업들은 차세대 제제나 부가가치가 높은 서비스를 제공함으로써 혁신을 꾀해야만 하며, 이는 궁극적으로 전 세계 시장의 임상의와 환자들이 이용할 수 있는 치료 선택지의 확대로 이어지고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 만성 판상 건선 시장 규모 : 치료 유형별
세계의 만성 판상 건선 시장 규모 : 약물 계열별
세계의 만성 판상 건선 시장 규모 : 투여 경로별
세계의 만성 판상 건선 시장 규모 : 질환 중증도별
세계의 만성 판상 건선 시장 규모 : 유통 채널별
세계의 만성 판상 건선 시장 규모 : 최종사용자별
세계의 만성 판상 건선 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.08.03Global Chronic Plaque Psoriasis Market size was valued at USD 29.5 Billion in 2024 and is poised to grow from USD 31.51 Billion in 2025 to USD 53.42 Billion by 2033, growing at a CAGR of 6.82% during the forecast period (2026-2033).
The global chronic plaque psoriasis market is marked by evolving therapies, diagnostics, and patient support services aimed at managing this prevalent autoimmune disease. The significant impact on patients' quality of life coupled with rising healthcare expenses drives demand for innovative treatments. While topical corticosteroids have traditionally dominated, biologics have introduced targeted immune modulation, enhancing therapeutic efficacy. The emergence of biosimilars has increased accessibility and affordability, particularly in developing markets. Investors are keenly observing advancements in treatment pipelines, especially as oral small molecules gain traction, offering improved convenience and safety. Enhanced adherence associated with oral Janus kinase inhibitors influences payer formularies, facilitating quicker adoption in specialty care. Manufacturers are increasingly investing in research and development of combination therapies to ensure sustained revenue growth and resilience.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Plaque Psoriasis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Chronic Plaque Psoriasis Market Segments Analysis
Global chronic plaque psoriasis market is segmented by treatment type, drug class, route of administration, disease severity, distribution channel, end user and region. Based on treatment type, the market is segmented into topical therapy, systemic therapy, biologic therapy and phototherapy. Based on drug class, the market is segmented into corticosteroids, vitamin D analogues, TNF-alpha inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitors, PDE4 inhibitors, TYK2 inhibitors and others. Based on route of administration, the market is segmented into topical, oral and injectable. Based on disease severity, the market is segmented into mild, moderate and severe. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, dermatology clinics, specialty centers and homecare settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Chronic Plaque Psoriasis Market
The heightened awareness among the public and healthcare professionals plays a crucial role in the early identification of chronic plaque psoriasis patients and the timely initiation of treatment plans. This proactive approach leads to a slower disease progression, improved quality of life, and greater patient involvement in the healthcare system. As more individuals seek treatment, the demand for effective therapeutic options continues to rise, driving market expansion as healthcare providers seek innovative solutions for diverse patient needs. Furthermore, educational initiatives enhance patient compliance and empower physicians to prescribe advanced treatment modalities, further contributing to the global market's growth trajectory.
Restraints in the Global Chronic Plaque Psoriasis Market
The Global Chronic Plaque Psoriasis market faces significant challenges due to the high costs associated with advanced therapies, which impose considerable financial strain on patients, insurers, and healthcare systems. This economic burden can lead to restrictive formulary placements and prior authorization requirements, ultimately limiting patient access and deterring healthcare providers from prescribing premium treatments. As a result, the penetration of innovative therapies into the market is slowed. Additionally, budget constraints often favor the use of generics or lower-cost alternatives, thereby diminishing the demand for cutting-edge solutions and restricting revenue opportunities for manufacturers. Affordability concerns also compel payers to seek rebates, introducing further complexities that may hinder product adoption.
Market Trends of the Global Chronic Plaque Psoriasis Market
The Global Chronic Plaque Psoriasis market is experiencing a significant transformation driven by the rise of biosimilars, which are making effective treatments more accessible and affordable. These biosimilars provide comparable efficacy to established biologics at reduced costs, thus broadening patient coverage and easing the strain on healthcare budgets. As payers increasingly endorse these alternatives, manufacturers are intensifying their development efforts, which, in turn, enhances market competition. This competitive landscape compels original biologic developers to innovate through next-generation formulations and additional value-added services, ultimately expanding treatment options available to clinicians and patients throughout the global market.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Chronic Plaque Psoriasis Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Topical Therapy
- Systemic Therapy
- Biologic Therapy
- Phototherapy
Global Chronic Plaque Psoriasis Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Corticosteroids
- Vitamin D Analogues
- TNF-alpha Inhibitors
- IL-17 Inhibitors
- IL-23 Inhibitors
- IL-12/23 Inhibitors
- PDE4 Inhibitors
- TYK2 Inhibitors
- Others
Global Chronic Plaque Psoriasis Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Topical
- Oral
- Injectable
Global Chronic Plaque Psoriasis Market Size by Disease Severity & CAGR (2026-2033)
- Market Overview
- Mild
- Moderate
- Severe
Global Chronic Plaque Psoriasis Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Chronic Plaque Psoriasis Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Dermatology Clinics
- Specialty Centers
- Homecare Settings
Global Chronic Plaque Psoriasis Market Size & CAGR (2026-2033)
- North America (Treatment Type, Drug Class, Route of Administration, Disease Severity, Distribution Channel, End User)
- US
- Canada
- Europe (Treatment Type, Drug Class, Route of Administration, Disease Severity, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment Type, Drug Class, Route of Administration, Disease Severity, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment Type, Drug Class, Route of Administration, Disease Severity, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment Type, Drug Class, Route of Administration, Disease Severity, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AbbVie Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- UCB S A
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Leo Pharma A S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
